The Problem

Standard cancer treatment is based on cancer type, stage, grade and overall patient health. While guidelines exist, each patient's unique tumor responds differently to therapy creating a need for personalized cancer treatment. Though certain genetic mutations correspond to specific therapies, use of general genetic data to predict targeted treatments has proven inexact and unsuccessful. Recently, functional assays using patient's tumors engrafted into mice (Patient derived xenografts) have emerged as potential models for assessing effectiveness of certain types of therapies. However, these models are costly, time consuming and fail to mimic the true of behavior of the human tumor.

Our Solution

Curesponse has developed a 3-dimensional tissue culture system for modeling cancer growth and drug response. The platform, preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body. We have harnessed the technology to create a personalized cancer diagnostic assay that can be used to determine drug response for a specific individuals tumor type. Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment. The patient’s tissue is cultured with the chosen drugs and analyzed with a proprietary evaluation system. The patient will then be informed which drug is the preferred therapy for their tumor, optimizing treatment and increasing their chances of survival. Moreover, the test can be used by pharmaceutical companies to expedite their drug development process as well as for clinical trials as a patient inclusion criteria.

1. Drug selection by physician & genomics

2. Cancer sample

removed from patient

3. 3D tissue culture system

4. Evaluation by a pathologist

The Curesponse Advantage

Curesponse has developed a 3-dimensional tissue culture system for modeling cancer growth and drug response. The platform, preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body. We have harnessed the technology to create a personalized cancer diagnostic assay that can be used to determine drug response for a specific individuals tumor type. Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment. The patient’s tissue is cultured with the chosen drugs and analyzed with a proprietary evaluation system. The patient will then be informed which drug is the preferred therapy for their tumor, optimizing treatment and increasing their chances of survival. Moreover, the test can be used by pharmaceutical companies to expedite their drug development process as well as for clinical trials as a patient inclusion criteria.

Caution: Investigational Technology. Not yet approved by Federal (or United States) Law to Clinical Use.

© 2018 All rights reserved to Curesponse

Website by: Anat Belinson

Curesponse logo